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Biochemical and cellular effects of roscovitine, a potent and selective inhibitor 
of the cyclin-dependent kinases cdc2, cdk2 and cdk5 
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Cyclin-dependent kinases (cdk) play an essential role in  the intracellular control of the cell division 
cycle (cdc). These kinases and their regulators are frequently deregulated in human tumours. Enzymatic 
screening has recently  led  to the discovery of  specific inhibitors of  cyclin-dependent kinases,  such as 
butyrolactone I, flavopiridol and the purine olomoucine. Among a series of C2, N6, N9-substituted ade- 
nines  tested  on  purified cdc2kyclin B, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpu- 
rine (roscovitine) displays high efficiency and high  selectivity towards some cyclin-dependent kinases. 
The kinase specificity of roscovitine was investigated with 25 highly purified kinases (including protein 
kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, 
c-src, v-abl). Most kinases are not significantly inhibited by  roscovitine. cdc2kyclin B, cdk2kyclin A, 
cdk2lcyclin E and cdkSlp35 only  are substantially  inhibited  (IC,,  values of 0.65, 0.7, 0.7 and 0.2 pM, 
respectively).  cdk4kyclin  D1  and  cdk6kyclin  D2  are  very  poorly  inhibited  by  roscovitine 
(IC,, >  100 pM). Extracellular regulated kinases erkl and erk2 are inhibited with an IC,,  of  34 pM and 
14 pM, respectively. Roscovitine reversibly arrests starfish oocytes and sea urchin embryos in late pro- 
phase.  Roscovitine inhibits  in  vitro  M-phase-promoting  factor activity  and  in  vitro  DNA synthesis in 
Xenopus egg extracts. It blocks progesterone-induced oocyte maturation of Xenopus oocytes and in vivo 
phosphorylation of the elongation factor eEF-1. Roscovitine inhibits the proliferation of mammalian cell 
lines with an average IC,,] of 16  pM. In the presence of roscovitine L1210 cells arrest in G1 and accumu- 
late in G2. In vivo  phosphorylation of vimentin  on  Ser55 by cdc2kyclin B is inhibited by roscovitine. 
Through  its  unique  selectivity for some cyclin-dependent  kinases,  roscovitine  provides  a  useful  anti- 
mitotic reagent for cell cycle studies and may prove interesting to control cells with deregulated cdc2, 
cdk2 or cdk5 kinase activities. 
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Regulation of  the cell division cycle has been the object of 
numerous studies during the last few years (see reviews in [l- 
51). Among cell cycle regulators, cyclin-dependent kinases (cdk) 
appear to play a central role in the initiation and ordering of cell 
cycle events (reviews in [6-91).  Cdk proteins are constituted of 
a catalytic subunit, the prototype of which is cdc2, and a regula- 
tory  subunit (cyclin). Eight human cdk proteins have been de- 
scribed so far: cdkl (= cdc2), cdk2-cdk8.  With the exception 
of cdk3, for which the regulatory cyclin has not yet been iden- 
tified [I 01,  all these proteins are regulated by the transient asso- 
ciation with one member of the cyclin family: cyclin A (cdc2, 
cdk5, cdk6), E (cdk2), H (cdk7). Each step of the cell cycle is 
cdk2), Bl-B3  (cdc2), C  (cdk8), Dl-D3  (cdc2,  cdk2, cdk4, 
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thought to be regulated by such cdk complexes: G1/S transition 
(cdk2lcyclin  E,  cdk3hnknown  cyclin,  cdk4kyclin  D1 -D3, 
cdk6kyclin DI, cdk8kyclin C), S phase  (cdk2kyclin A), G2 
(cdc2kyclin A), G2/M transition (cdc2kyclin B, cdk7kyclin H). 
Other  cdc2-related  kinases  and  cyclins  have  been  sequenced 
which  await  identification  of  their  regulatory  partners  and  of 
their cell cycle regulatory functions. Cdk proteins are finely reg- 
ulated  by  post-translational  (phosphorylationldephosphoryla- 
tion)  modifications,  transient  associations  with  other  proteins 
and intracellular translocations. The regulators include activators 
(cyclins,  cdk7kyclin  H,  cdc25 phosphatases),  the  interacting 
subunits  and  plScdk-Bp,  natural  inhibitors  (pl  6"K4A, 
p15"K4B, ~18"~~',  p27K'p',  ~57~'",  p21c'p1) and  inhibiting  en- 
zymes (weel, mikl, mytl, KAP) (reviewed in [8, 91). The crys- 
tal structures of  cdk2 Ill]  and of cdk2kyclin A [I21 have been 
recently determined. 
Human tumour development is associated with numerous al- 
terations  of  cdk  proteins  and  their  regulators  (reviews in  [13, 
141): overexpressions of  cyclins D and E in  a large variety of 
tumours, overexpression of cdc2, oncogenicity of the D cyclins, 
oncogenicity of cyclin A in a human hepatic cancer, oncogenic- 
ity of the cdc25 phosphatase, abnormal temporal expression of 528  Meijer et al. (Eur: J. Biochem. 243) 
cyclins in human tumour cell lines, presence of  INK4-resistant 
cdk4 in some tumours, high frequency deletions and mutations 
of INK4 in human tumours cell lines and primary tumours, tran- 
scriptional regulation  of  p21"p'  by  the tumour  suppressor p53, 
etc. 
The frequent deregulation of cdk proteins and their regula- 
tors in cancer and the therapeutic potential of natural inhibitors 
[I 51 has stimulated an active search for chemical cdk inhibitors. 
A few years ago we set up a simple screening test using affinity- 
purified p34"'"'/cyclin  BCd'l7 as a target [16]. The enzyme activ- 
ity is assayed, in the presence of  potential inhibitors, using his- 
tone H1 and  ["PIATP.  Using this or very closely related meth- 
ods, five types of  cdk inhibitors have been described so far: a) 
staurosporine [16, 171, b) butyrolactone I [18-201,  c) flavopiri- 
do1 [21-231,  d) suramin [24] and e) olomoucine [25-281.  The 
chemical, enzymatic and cellular properties of these compounds 
have been reviewed [29, 301. 
The purine olomoucine displays a quite narrow selectivity: 
among 35 kinases tested, it only inhibits cdc2, cdk2, cdk5, and 
erkl to a lesser extent  [ 27  1.  The position  of olomoucine in the 
ATP binding pocket of cdk2 has been determined by analysis of 
an  olomoucine/cdk2  co-crystal  [31].  Interestingly  the  purine 
rings of olomoucine and ATP are orientated in a totally different 
manner. Recently, olomoucine  was found to stimulate massive 
apoptosis in cells which have been arrested in G2 by  the use of 
DNA-damaging agents [32]. In contrast cdk inhibitors (olomou- 
cine  and  flavopiridol)  display  anti-apoptotic  activity  in  post- 
mitotic  neuronally  differentiated  PC12  cells  and  sympathetic 
neurons [33].  These encouraging results led us to evaluate other 
C2, N',  N9-substituted adenines as potential cdk inhibitors [34]. 
We here report the biochemical properties and cellular effects of 
a novel inhibitor, 2-(R)-( 1  -ethyl-2-hydroxyethylamino)-6-benzy- 
lamino-9-isopropylpurine  (roscovitine). The molecular  interac- 
tion of roscovitine with cdk proteins is described in the preced- 
ing paper [34]. 
EXPERIMENTAL PROCEDURES 
Chemicals.  Sodium  orthovanadate,  1 -methyladenine 
(IMeAde), EGTA. EDTA, Mops, glycerol 2-phosphate, dithio- 
threitol,  sodium  fluoride,  nitrophenyl  phosphate,  leupeptin, 
aprotinin,  soybean  trypsin  inhibitor,  benzamidine,  histone  H1 
(type 111-S), myelin basic protein, casein, protamine sulfate, iso- 
propyl  pa-thiogalactopyranoside,  CNBr-activated  Sepharose 
4B, Luria-Bertani broth base, glutathione and glutathione-agar- 
ose beads were obtained from Sigma Chemicals. 
Roscovitine was synthesized by  one of  us (Havlicek et al., 
unpublished) and  dissolved  as a  10-50mM  stock solution in 
dimethylsulfoxide  (Me,SO).  It  was  diluted  to  5- 10 mM  in 
Me,SO just prior to use in aqueous buffers.  Final MezSO con- 
centration in  the reaction  mixture was less  than  1% (by  vol.). 
[y-12P]ATP  (PB 168) was obtained from Amersham. 
Retinoblastoma  protein  (conjugated  to  glutathione  S-trans- 
ferase) was expressed in bacteria and purified on glutathione- 
Sepharose beads as previously described 127, 3.51. 
Monoclonal  anti-PSTAIRE  antibodies  (raised  against  the 
EGVPSTAIRESLLKEGGC  peptide)  were  generously  donated 
by  Dr  M.  Yamashita  (Sapporo).  4A4  monoclonal  antibodies 
(raised  against  the  SLYSSS(P)PGGAYC  peptide)  recognizing 
[Ser(P)5s]vimentin  were provided by Drs N. Inagaki and M. Ina- 
gaki (Tokyo). 
Buffers. Homogenization  buffer:  60 mM glycerol  2-phos- 
phate,  15 mM p-nitrophenyl  phosphate,  25 mM  Mops  pH 7.2, 
15  mM EGTA,  15 mM  MgCl,,  1 mM dithiothreitol,  1 mM so- 
dium vanadate, l mM NaF, l mM phenyl phosphate, 10  pg leu- 
peptidml, 10 pg aprotinidml, 10 pg soybean trypsin inhibitor/ 
ml and 100 pM benzamidine. 
Buffer C: homogenization buffer but 5 mM EGTA, no NaF 
and no protease inhibitors. 
Preparation  of  starfish  M-phase  oocyte  extracts.  For 
large-scale oocyte extracts preparations,  gonads were removed 
from ripe  Marthasterias glacialis  and  incubated  with  10 pM 
1MeAde in Millipore-filtered natural sea water until spawning ; 
by that time, all the oocytes had entered the M phase. Oocytes 
were then removed from the incubation medium by centrifuga- 
tion, directly frozen  in liquid  nitrogen and kept at -80°C [27, 
361.  M-phase  oocytes  were  homogenized  in  homogenization 
buffer at a ratio of 2 g oocytes/ml buffer. After a 45-min centrif- 
ugation at 100000  g, the supernatant was recovered and directly 
used  for  affinity-chromatography  purification  of  the  ~34c"~'/ 
cyclin B kinase on p9CKSh"-Sepharose  beads  as described  [27, 
351. 
Enzymes. Kinases activities were assayed at 30°C in buffer 
C  (unless otherwise  specified). Blank  values  were  substracted 
from the data and activities calculated as molar amount of phos- 
phate incorporated in protein acceptor during a 10-min incuba- 
tion.  Controls  were  performed  with  appropriate  dilutions  of 
Me,SO.  In  a few  cases,  phosphorylation  of  the  substrate was 
assessed by autoradiography after SDS/PAGE. 
p34'"'2/cyclin  B was purified from M-phase starfish (M.  gla- 
cialis) oocytes by  affinity  chromatography  on p9CKSh"-Sephar- 
ose beads, from which it was eluted by free p9CKSh"  as described 
above [35-371.  It was assayed with 1  mg histone Hl/ml, in the 
presence of  15 pM  [y-"P]ATP  (3000 Ci/mmol; 1 mCi/ml) in  a 
final volume of 30 p1  [27]. After a 10-min incubation at 30"C, 
25-pl  aliquots  of  supernatant  were  spotted  onto  pieces 
(2.5 X3 cm) of Whatman P81 phosphocellulose paper, and, after 
20 s, the filters were washed five times (for at least 5 min each 
time) in  a solution  of  10ml phosphoric  acid/l  water. The wet 
filters were transferred into 6-ml plastic scintillation vials, 5 ml 
ACS  (Amersham)  scintillation fluid was added and  the  radio- 
activity measured in a Packard counter. The kinase activity was 
expressed as molar amount of phosphate incorporated in histone 
H1 during a 10-min incubation or as a percentage of  maximal 
activity. 
p33'"kz/cyclin A and p33"dh2/cyclin  E (kindly provided by W. 
Harper) were reconstituted from extracts of  sf9 insect cells in- 
fected with various baculoviruses. Cyclins A and E were fusion 
proteins with glutathione S-transferase and the complexes were 
purified  on  glutathione-agarose  beads.  Kinase  activities  were 
assayed with  1 mg/ml histone H1, in the presence of 15  pM  [y- 
12P]ATP,  during 10 min, in a final volume of 30 pl, as described 
for the p34"dc'/cyclin B kinase. 
p33"lk'/p35  (provided by J. Lew and J. H. Wang) was puri- 
fied from bovine brain  [38], excluding the Mono S chromato- 
graphic step. The active fractions from the Superose 12 column 
were pooled and concentrated to a final concentration of approx- 
imatively 25 pg enzyme/ml. The kinase was assayed with 1 mg/ 
ml  histone  HI  in  the  presence  of  15 pM  [;J-'~P]ATP,  during 
10 min in a final volume of  30 pl, as described for the p3Qd"l 
cyclin B kinase. 
p33'"h"/cyclin D1 was obtained from insect cell lysates (pro- 
vided by w. Harper). Cdk4 was a fusion protein with glutathione 
S-transferase and the  active complex  was purified  on  glutathi- 
one-agarose beads. Its kinase activity was assayed with purified 
retinoblastoma  protein  (complexed  with  glutathione-S-transfer- 
ase) in the presence of  15 pM [y-'*P]ATP, in a final volume of 
30 p1.  After  a  15-min  incubation,  30 p1  2 XLaemmli  sample 
buffer was added. The phosphorylated substrate was resolved by 
10  % SDSIPAGE and analysed by  autoradiography by overnight 
exposure to Hyperfilm MP and densitometry. Meijer et al. (Em  J. Biockem. 243)  529 
p33""kh/cyclin  D2 (provided by  M. Meyerson) was obtained 
from insect cell lysates [39]. It was assayed with purified retino- 
blastoma protein  (complexed with  glutathione-S-transferase)  in 
the presence of  15 pM  [y-"P]ATP  in  a final volume of  30 pl. 
After a 30-min incubation, 30 p12X Laemmli sample buffer was 
added. The phosphorylated substrate was resolved by 10%  SDSI 
PAGE and analysed by  autoradiography by  overnight exposure 
to Hyperfilm MP and densitometry. 
MAP kinase erkl  [40] (tagged with glutathione-S-transfer- 
ase; cloned from a human HepG2 library; provided by D. Char- 
est and s. L.  Pelech),  was  expressed  in  bacteria,  purified  on 
glutathione-agarose beads and assayed with  1 mg  myelin basic 
protein/ml  in  the  presence  of  15 pM  [y-"P]ATP  as  described 
above for the p34'9cyclin  B kinase. His-tagged erkl and erk2 
(provided by M. Cobb) were activated in vitro by mitogen-acti- 
vated protein kinase kinase, purified (Ni-affinity and Mono Q) 
and assayed as described above during 10  min in a final volume 
of  30 pl. 
Protein kinase C isoforms were purified from baculovirus- 
infected  sf9 insect cells  and  assayed  with  1 mg/ml  protamine 
sulfate in the presence  of  15 pM  [y-'2P]ATP, during  10 min  at 
30"C, in a final volume of 30 pl. Phosphorylated protamine sul- 
fate was recovered on Whatman P81 phosphocellulose paper as 
described for the cdc2 kinase. 
The  catalytic  subunit  of  CAMP-dependent protein  kinase 
(provided  by  S.  Lohmann),  purified  from  bovine  heart,  was 
assayed with 1 mg histone Hl/ml, in the presence of  15 pM  [y- 
"PIATP  as described for the p34'd'2/cyclin B kinase. 
cGMP-dependent protein kinase (provided by F.  Hofmann), 
purified to homogeneity from bovine  tracheal  smooth muscle, 
was assayed with 1 mg histone Hl/ml, in the presence of  15 pM 
[y-3zP]ATP  as described for the p34'"''/cyclin  B kinase. 
Casein kinase 2 (provided by  L. Pinna)  was  isolated from 
rat liver cytosol and assayed with 1 mg casein/ml and 15 pM [y- 
32P]ATP.  The substrate was spotted on Whatmann  3MM filters 
and washed with 10% (mass/vol.) trichloroacetic acid. 
Myosin  light  chain  kinase,  purified  from  chicken  gizzard 
(provided by T. J. Lukas and M. Watterson) was assayed in the 
presence of  100 nM calmodulin, 100 pM CaCI,,  SO mM Hepes, 
5 mM MgCI,, 1 mM dithiothreitol and 0.1 mg BSA/ml at pH 7.5 
using a synthetic peptide based on the smooth-muscle myosin 
light-chain  phosphorylation  site  (KKRPQRATSNVFAM, 
50 pM) and in the presence of 15 pM [y-"PIATP,  in a final vol- 
ume of 50 pl. Incorporation of radioactive phosphate was moni- 
tored on phosphocellulose filters as described above. 
ASK-y, a plant  homologue of  GSK-3, was expressed  as a 
glutathione-S-transferase fusion protein in Escherichia coli [411 
and purified on glutathione-agarose. ASK-? kinase was assayed, 
for 10 min at 30"C, with 5 pg myelin basic protein, in the pres- 
ence of 15 pM [Y-~~PIATP,  in a final volume of 30 p1. The phos- 
phorylated myelin basic protein was recovered on Whatman P81 
phosphocellulose paper as described for the p34'd'2/cyclin B ki- 
nase. 
Insulin receptor tyrosine kinase domain (CIRK-41) [42] was 
overexpressed  in  a baculovirus  system  and purified  to  homo- 
geneity  (provided by  H.  Y.  L.  Tung).  Its  kinase  activity  was 
assayed, for 10 min at 30"C, with 5 pg Raytide (Oncogene Sci- 
ences), in the presence of  15 pM [y-"PIATP,  in a final volume 
of  30 pl. The phosphorylated Raytide was recovered on What- 
man  P81 phosphocellulose  paper  as described  for  the p34'"'/ 
cyclin B kinase. 
c-src kinase was purified from infected Sf9 cells. The v-abl 
kinase  was  expressed  in  E. coli  and affinity purified  on  IgG- 
Affigel  10. Both kinases  (provided by  Dr  Helmut Mett)  were 
assayed for 10 rnin  at 30°C, with 5 pg Raytide, in the presence 
of 15 pM [y-'2P]ATP, in a final volume of 30 pl. The phosphory- 
lated Raytide was recovered on Whatman P81 phosphocellulose 
paper as described for the p34"d'z/cyclin B kinase. 
Electrophoresis and western blotting. Proteins  bound  to 
p9CKSh"-Sepharo~e  beads  (starfish  cdc2)  or  crude  extracts 
(L1210) were denatured with 2 X Laemmli sample buffer. Sam- 
ples were run on 10%  SDS/polyacrylamide gels. Proteins were 
transferred  from  the  gel  to  a  0.1-pm  nitrocellulose  sheet 
(Schleicher & Schull) in a milliblot-SDE system (Millipore) for 
30 rnin at  2.5 mA/cmZ  in transfer buffer. Subsequently, the filter 
was blocked with 5%  low fat milk in 50 mM TridHCl, pH 7.4, 
250 mM  NaCI, 0.1% Tween-20 (Tris/NaCI/Tween-20) for  1 h. 
The filter was then washed with (Tris/NaCI/Tween-20) and incu- 
bated for 1  h with  the first antibodies (anti-PSTAIRE, 1 :2000; 
anti-[Ser(P)5sl vimentin,  1  mg/ml).  After  four  washes  (one of 
20 rnin  three  of  5 min)  with  (Tris/NaCI/Tween-20), the  nitro- 
cellulose sheet was treated for 1 h with horseradish-peroxidase- 
coupled  secondary  antibodies  diluted  in (Tris/NaCI/Tween-20) 
(1 : 1000).  The filter was then washed five times (one of  20 min, 
four of  5 min) with (Tris/NaCI/Tween-20) and analysed by  en- 
hanced  chimioluminescence  with  ECL  detection  reagents  and 
hyperfilm MP. 
Sea  urchin embryos. Sea  urchins  (Sphaerechinus  grunu- 
luris) were collected by  diving in Brittany and kept in running 
sea water until use. Shedding of gametes was induced by  injec- 
tion of  0.2 ml 0.2 M acetylcholine. Sperm was collected dry and 
kept  undiluted at  +4"C.  Eggs  were collected  in Millipore-fil- 
tered natural  sea water  (NSW). They  were washed once  with 
NSW and resuspended as a 10% (by vol.) suspension. To facili- 
tate fertilisation membrane elevation, 0.1  % (masshol.) glycine 
was added to the egg suspension prior to fertilisation. Sperm was 
diluted just before insemination (1 drop dry sperm/S ml NSW; 1 
drop of  this dilution/lO ml  egg  suspension). At  2-3  min  after 
sperm addition, the eggs were checked for successful fertilisa- 
tion (100% in all experiments) and excess sperm was removed 
by washing the eggs once with NSW. All experiments were per- 
formed at +  18  "C. Roscovitine was added 60 min after fertilisa- 
tion. Embryos  were scored for cleavage under the microscope 
(Nomarski phase contrast). 
Starfish oocyte maturation. Starfish  (Marthasterias gla- 
cialis) oocytes  were  prepared,  maturation induced  and  ~34'"~ 
analysed  as  previously  described  [43].  The  level  of  tyrosine 
phosphorylation  of  ~34"~"  was  analysed  by  western  blotting 
with anti-PSTAIRE antibodies after SDS/PAGE of  the ~9''~~~''- 
affinity-bound proteins, as described above. 
Activity of  M-phase promoting factor (MPF) and DNA 
synthesis in Xenopus egg extracts. Xenopus egg extracts and 
demembraned Xenopus sperm nuclei were prepared as described 
previously  [44, 451 and stored in liquid nitrogen until required. 
For MPF inhibition, extracts of  eggs undergoing mitosis were 
supplemented  with  25 mM  phosphocreatine,  5 pglml  creatine 
phosphokinase and demembraned sperm nuclei (final concentra- 
tion: 2 ng DNA/pl extract). After 1.5 h at 21"C, roscovitine was 
added at various concentrations. MPF inhibition was then moni- 
tored by assessing the percentage of  sperm nuclei that had been 
assembled into interphase nuclei, possessing a complete phase- 
dense  nuclear  envelope.  For  DNA  synthesis  assays,  extracts 
from metaphase-arrested eggs were supplemented with 25 mM 
phosphocreatine, 5 pg/ml creatine phosphokinase, 250 pg/ml cy- 
cloheximide,  [a-12P]-dATP  at 50 pCi/ml.  Demembraned  sperm 
nuclei were added to a final sperm concentration of  4 ng DNA/ 
p1  extract. Roscovitine was added after 20 min DNA synthesis 
was assessed by releasing extract into interphase by the addition 
of 0.3 mM CaCI, and measuring the total amount of  [a-32P]dATP 
incorporation  after  3 h  by  trichloroacetic  acid  coprecipitation 
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Fig. 1. Roscovitine doselresponse curves for p34'*"z/cyclin  B, p33"dkz/~y~lin  A, p33"'k2/cyclin  E, p33'"'-'/p35, p3Fdk4/cydin  D 1 and p4Wdk6/cyclin 
D2 protein kinases. Enzyme  activities  were  assayed  as described  under  Experimental  Procedures  in  the presence  of  increasing concentrations 
of  roscovitine.  Gels  are also shown for p33c"k"/cyclin  D1  and  p40'""lyclin  D2 protein  kinases ; GST-Rb, retinoblastonia  protein  conjugated to 
glutathione S-transferase. 
Xenopus laevis oocytes. X. laevis oocytes were prepared as 
described previously [46]. Various concentrations of roscovitine 
were added 4 h before addition of  1 pM progesterone. The per- 
centage of  germinal vesicle breakdown was recorded  8 h later. 
In another set of  experiments,  oocytes were treated with 0, 50 
or 100 pM roscovitine prior to 1 pM progesterone. In vivo phos- 
phorylation of  elongation factor  1 subunits p, y  and 6 was as- 
sessed after immunoprecipitation of  the whole complex  [46] in 
"P-labelled  oocytes. 
National Cancer Institute (NCI) disease-oriented in  vitro 
screen. 60 human  tumour  cell  lines  comprising  nine  tumour 
types  [47] were  cultured  for  24 h prior  to  a  48-h  continuous 
exposure  to  0.01 -  100 pM  roscovitine.  A  sulforhodaminine B 
protein assay was used to estimate the cytotoxicity. 
L1210 cell culture. L1210  cells  taken  from  exponentially 
growing  cultures  in  RPMT-1640  medium  supplemented  with 
10%  foetal  calf  serum,  penicillin  and  streptomycin,  were 
counted  using  a hemocytometer,  seeded  at  SX104 cells/ml  in Meijer et al. (Em  J. Biochem. 243)  531 
Table 1. IC5,,  values for roscovitine and olomoucine added to various 
purified enzymes. Enzyme activities were assayed as described in Ex- 
perimental Procedures, in the presence  of increasing concentrations  of 
roscovitine and olomoucine. IC,,  values were calculated from the dose/ 
response curves. When no inhibitory effect was observed (-),  the high- 
est concentration tested is given in parentheses. Some data for olomou- 
cine was originally presented by  Vesely et al. [27]. GST-, conjugated to 
glutathione S-transferase. 
Enzyme  IC,,  for 
roscovitine  olomoucine 
cdc2/cyclin B 
cdk2/cyclin A 
cdk2lcyclin E 
cdk4/cyclin D1 
cdkYp35 
cdkhkyclin D3 
GST-erkl 
erkl 
erk2 
Protein kinase C a 
Protein kinase C fil 
Protein kinase C 
Protein kinase C 1’ 
Protein kinase C 6 
Protein kinase C E 
Protein kinase C y~ 
Protein kinase C ( 
CAMP-dependent protein kinase 
cGMP-dependent protein kinase 
Myosin light-chain kinase 
Casein kinase 2 
ASK-? (plant GSK-3) 
Insulin-receptor tyrosine kinase 
c-src 
v-abl 
0.65 
0.7 
0.7 
0.16 
> 100 
> 100 
30 
34 
14 
> 100 
> 100 
> 100 
100 
>  1000 
> 100 
> 100 
>I000 
>  1000 
-  (1000) 
90 
-(1000) 
220 
70 
250 
>loo0 
7 
7 
7 
>  1000 
3 
> 250 
30 
50 
40 
>I000 
>  1000 
>loo0 
800 
>  1000 
>  1000 
930 
>  1000 
>2000 
>2000 
>  1000 
>2000 
130 
400 
-  (1 000) 
-(  100) 
tissue-culture 96-wells plates in the presence or absence of vari- 
ous concentrations of  roscovitine or olomoucine and incubated 
at 37°C under 5% CO,.  For reversion of the roscovitine effect, 
L1210  cells  cultured  two  days in  the  presence  or absence  of 
roscovitine were washed in phosphate-buffered saline to remove 
any  trace of  the drug, counted  and reseeded  in  fresh medium 
containing no drug. Cell growth was monitored daily using the 
microculture tetrazolium assay [48]. Cell cycle analysis was per- 
formed on cells that were fixed in ethanol, treated with 100 pgl 
ml  RNase and stained with propidium  iodide  [49]. We  used a 
Coulter  EPICS  Elite  flow  cytometer  for  acquisition  and  the 
Multicycle software (Phoenix Flow systems) for analysis of  the 
data. All  assays were performed  in  triplicate  and experiments 
repeated at least twice. 
In vivo phosphorylation of vimentin. To investigate in  vivo 
phosphorylation of  vimentin by  cdc2 kinase, cells were treated 
or not with 60 pM roscovitine for 48 h prior to exposure to 10 ng 
colcemid/ml for another 2 h. Cell extracts were then run on 10% 
SDSPAGE and western blots performed using the 4A4 antibod- 
ies. These antibodies cross-react with cdc2-phosphorylated  vi- 
mentin, but not with vimentin phosphorylated by  other kinases 
nor with unphosphorylated vimentin [SO]. 
RESULTS 
In the preceding paper [34], we have described the identifi- 
cation  of  roscovitine  and  its  molecular  interaction  with  cdk2. 
Here we describe an investigation into its enzymatic selectivity 
and cellular effects. 
Kinase specificity of the roscovitine inhibitory effect. Roscov- 
itine  was tested against various cdk proteins  (Fig. 1;  Table 1). 
IC,,, values for cdc2kyclin B, cdk2/cyclin A, cdk2/cyclin E and 
cdkYp3S  are respectively  0.65, 0.7, 0.7  and 0.16 pM  (Fig. 1). 
When compared with olomoucine, roscovitine thus showed a 10- 
fold higher efficiency towards its cdc2 and cdk2 targets, a 20- 
fold higher efficacy towards cdk5. As observed for olomoucine 
[27], roscovitine had a very limited effect on the cdk4/cyclin D1 
and  cdk6/cyclin  D2  kinases  (IC,,  values  >  100 pM)  (Fig. 1). 
This lack of  effect was confirmed with cdk4 from several inde- 
pendent sources (data not shown). Under identical assay condi- 
tions,  ~16’”~~~  inhibited  cdk4/cyclin  D1  and  cdk6kyclin  D2 
(data not shown). 
Roscovitine  was  tested  on  a variety  of  highly  purified ki- 
nases (Table 1).  Kinase activities were assayed with appropriate 
substrates (histone HI, myelin basic protein, casein, etc.), with 
15  pM ATP and in the presence of  increasing concentrations of 
roscovitine. IC,,  values were calculated from the dose/response 
curves  (Table 1). Most  kinases  were  poorly  or not  inhibited. 
Although  roscovitine  displayed  a  10-fold  higher  efficacy 
towards its cdk targets when compared with olomoucine, both 
compounds  displayed  a  similar  inhibitory  action  on  erkl and 
erk2 (Table 1, Fig. 2). A 40-fold higher roscovitine  concentra- 
tion  was needed to inhibit  erkl similarly to cdc2 (20-fold for 
erk2). The selectivity of roscovitine was therefore about 10-fold 
higher than that of  olomoucine. 
Cell cycle effects of roscovitine: oocytes and embryos. The 
cellular effects of olomoucine have been described recently [28]. 
We selected a few cellular models to investigate the cellular ef- 
fects of roscovitine (Figs 3-8). 
Prophase-arrested starfish oocytes were treated with various 
concentrations of  roscovitine prior to exposure to lMeAde, the 
hormone which triggers the prophase/metaphase transition 151 1. 
Roscovitine inhibited nuclear envelope breakdown with an IC,, 
of  5 pM (Fig. 3A). IC,, for olomoucine is 30 pM [271. As pre- 
viously  observed  with  olomoucine,  roscovitine  slowed  down, 
but  did  not  inhibit,  the  in  vivo tyrosine  dephosphorylation  of 
p3edcZ  as monitored by  its change  of  electrophoretic mobility 
with antibodies against PSTAIRE (Fig. 3B). In other words, it 
did  not  inhibit  the  activation  of  cdc2, but  its activity. p34cdL2 
tyrosine dephosphorylation is catalysed by  the cdc25 phospha- 
tase and normally precedes the cdc2 kinase activation at the G2/ 
M transition [43]. The cdc2 kinase phosphorylates and hyperac- 
tivates  the  cdc25 phosphatase  [52-541.  In  addition,  the  cdc2 
kinase phosphorylates and inactivates the wee1 kinase [55  -591. 
These positive feedback loops may thus have been interrupted 
by  roscovitine  at the cdc2 kinase  level, resulting  in a slowed 
down dephosphorylation. 
Roscovitine was next tested on mitotic sea urchin embryos. 
When added 60 min after fertilisation, roscovitine was found to 
arrest  cells  in  late  prophase  in  a  dose-dependent  manner 
(Fig. 4A;  IC,,  of  10 pM). A large nucleus could be observed in 
the roscovitine  arrested  eggs  (Fig. 4B). This arrest  was  com- 
pletely reversible : following  washing with sea water, the eggs 
re-entered mitotic cycles and developed into normal plutei (data 
not shown). This was observed even with highest concentration 
of  roscovitme,  100 pM.  At  100 pM,  olomoucine  only  slows 
down the prophase/metaphase transition, without arresting cells 
in prophase [28]. 
The effects of roscovitine were next assessed using Xennpus 
egg extracts [44]. Mitotic egg extracts were incubated with ros- 
covitine  and  sperm  chromatin.  In  roscovitine  concentrations 532  Meijer et al. (EM J. Bioclzenz. 243) 
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Fig.2. Effects of roscovitine and olomoucine on erkl and erk2. Enzyme activities were assayed as described under Experimental Procedures in 
the presence of  increasing concentrations of roscovitine. 
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Fig. 3. Effects of roscovitine on starfish oocyte maturation and on in 
vivo tyrosine dephosphorylation of p34"'*. G2-arrested oocytes were 
treated for 15 min with increasing concentrations of roscovitine prior to 
addition  of  1 pM  1-MeAde; after 30 min  the  percentage of  germinal 
vesicle breakdown (GVBD) was scored (A). (B) Starfish oocytes were 
treated or not (control) with 10 pM roscovitine for IS min prior to addi- 
tion of  1 pM 1-MeAde at time zero. Extracts prepared  at various times 
were loaded on p9rK"h"-Sepharo~e  beads. The bound proteins were re- 
solved by  SDS/PAGE prior  to iinmunoblotting with  antibodies against 
PSTAIRE. The immunoblots at  the level of  ~34"'~~  are presented.  The 
upper, phosphorylated, and lower, dephosphorylated, forins of p34'"'2  are 
detected. 
ranging over 0-5  pM chromosomes appeared highly condensed 
and  nuclear  envelopes broke down. At  10 pM roscovitine and 
above,  interphase  nuclei  remained  with  partially  decondensed 
chromatin  and  an  intact  nuclear  envelope,  showing  that  MPF 
activity was inhibited (Fig. 5 ;  IC,,  of  5 pM). Inhibition of DNA 
synthesis was assessed as described for olomoucine  [27]: ros- 
covitine  and  sperm chromatin  were  added  to  a  metaphase-ar- 
rested egg extract. The extract was then released into interphase 
by addition of CaCI, [44, 451 and, 3 h later, total DNA synthesis 
was measured by  [a-"PIdATP  incorporation  in trichloroacetic- 
acid-precipitable material. Replication was inhibited by roscovi- 
tine with an IC,,  of  15 pM (Fig. 5). 
Prophase-arrested  Xenopus  oocytes  were  simultaneously 
treated  with  various concentrations  of  roscovitine prior to pro- 
gesterone addition. A dose-dependent inhibition of oocyte matu- 
ration  was observed (Fig. 6A; 1C5():  25 pM). The effect of  ros- 
covitine on the in  vivo activity of the cdc2 kinase was estimated 
on  the  phosphorylation  of  the  elongation factor  subunits. This 
cdc2 substrate is phosphorylated on its  y  subunit (Thr230) and 
on its 6 subunit  (Thr122  and  an  unidentified  Ser)  [46]. The 
whole  elongation  factor  1 complex  was  immunoprecipitated 
from  'ZP-labelled  oocytes  (prophase-arrested,  progesterone- 
treated, progesterone- and roscovitine-treated), resolved by SDSI 
PAGE and autoradiography. Roscovitine inhibited the phosphor- 
ylation of eEF-1 y  and 6 (Fig. 6B). 
Cell cycle effects of roscovitine: mammalian cell lines. Ros- 
covitine (0.01 -100  pM; 48-h exposure) was tested on the NCI 
disease-oriented in vitro screen, i.e. 60 human tumour cell lines 
comprising  nine  tumour  types  (leukemia,  non-small  cell  lung 
cancer, colon cancer, central nervous system cancer, melanoma, 
ovarian cancer, renal cancer, prostate cancer, breast cancer). All 
cell  lines  displayed  a  similar  sensitivity  to  roscovitine.  The 
average IC,,  was 16 pM (60.3 pM for olomoucine [28]). No cor- 
relation  was  observed  between  the  sensitivity  of  cell  lines  to 
roscovitine and the presence of wild-type or mutated p53. The 
COMPARE analysis method showed that the effects of roscovi- 
tine and flavopiridol were comparable. 
We next investigated the effects of roscovitine on the growth 
of the L1210 cell line (Figs 7 and 8). Cells were grown in  the 
presence of various roscovitine concentrations and their growth 
monitored after two and three days. A clear-cut dose-dependent 
inhibition of  growth was observed  (Fig. 7A). The curves were 
essentially the same after two and three days of culture (data not 
shown) as observed in the NCI in vitro screen. Roscovitine was Meijer et al. (EM J. Biochem. 243)  533 
Roscovitine concentration (pM) 
Fig.4. Effects of roscovitine on sea urchin embryos mitotic cycle. Eggs were fertilised at time zero and various concentrations  of  roscovitine 
were added 60 min later. The percentage of divided embryos was monitored 120 min after fertilisation (A). Embryos were arrested in late prophase  - 
with an exceptionally large nucleus (B). 
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Fig.5.  Effects of  roscovitine  on  in  vitro  DNA  synthesis  and MPF 
activity. Two different  titrations  were performed  on Xenopus  extracts 
(see text): (0)  inhibition of MPF (percentage of  assembled nuclei) and 
(0)  inhibition of  DNA synthesis. 
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approximatively fourfold more efficient at inhibiting cell growth 
when  compared  to olomoucine  (1C5": 40 pM  and  160 pM, re- 
spectively). Although most cells were viable (96  ?  2 % Trypan 
blue exclusion) following a 48-h treatment with 60 pM roscovi- 
tine,  they  remained  irreversibly  arrested,  even  after extensive 
washing (data not shown). Cells exposed to 120 pM roscovitine 
died rapidly. The effects of roscovitine on cell cycle distribution 
was next investigated by flow cytometry. At 60 pM roscovitine, 
cells remained arrested in G1 and accumulated in G2 (Fig. 7 B). 
In an effort to identify the in vivo molecular target of roscov- 
itine, we made use of the 4A4 monoclonal antibodies described 
by  Tsujimura et al. [50].  These antibodies very specifically re- 
cognize [Ser(P)"]vimentin,  but not unphosphorylated vimentin, 
nor vimentin phosphorylated by  various kinases (CAMP-depen- 
dent protein kinase,  protein  kinase C, Caz+-calmodulin-depen- 
dent protein kinase). The Ser55 residue of  vimentin is specifi- 
cally phosphorylated  by the cdc2 kinase as cells enter mitosis 
[SO].  Cells were treated or not with 60 pM roscovitine for 48 h 
and then exposed  to 10 ng colcemid/ml  for another 2 h.  Total 
proteins  were  extracted  and  resolved  by  SDSPAGE  prior  to 
western blotting with 4A4 antibodies (Fig. 8). The non-treated 
cells  arrested  in  metaphase  and  accumulated  cdc2-phosphory- 
P- 
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Fig.6. Roscovitine inhibits Xenopus  oocyte maturation and the it?  vivo phosphorylation of  eEF-1  y  and 3.  (A) Oocytes  were exposed  to 
progesterone and treated with increasing concentrations of  roscovitine. The percentage of germinal vesicle breakdown (GVBD) was scored. (B) In 
vivo phosphorylation  of  eEF-1  y  and 6, immunoprecipitated  from "P-labeled  oocytes (control, progesterone-treated,  progesterone  + roscovitine- 
treated). 534  Meijer et al. (Eur J. Biochem. 243) 
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Fig.7. Roscovitine inhibits the  growth of L1210 cells and arrests cells in G2M. (A) L1210 cclls were exposed to  various concentrations of 
roscovitine (0)  or olomoucine (0).  Their growth was monitored after two days and is presented as a percentage of the growth of  control untreated 
cells (mean 2  SD). (Bj Cells were first grown for 48 h in  the absence or presence of  60 pM roscovitine. The cell cycle distribution was then analysed 
as described in Experimental Procedures; data is presented as mean 2 SD. 
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Fig. 8. Roscovitine inhibits  in  vivo phosphorylation of  vimentin on 
cdc2-specific sites. L1210 cells were grown for 48 h in the absence or 
presence of 60 pM roscovitine. They  were then exposed  to  10 ng col- 
cemid/ml for another 2 h. Cells were then pelleted, frozen in liquid nitro- 
gen and their proteins resolved by  SDS/PAGE and analysed by  western 
blotting using 4A4 monoclonal antibodies. These antibodies specifically 
rccognize [Ser(P)"]vimentin,  i.e. vimentin phosphorylated only by cdcU 
cyclin B. 
Iated vimentin. In contrast, roscovitine-treated cells did not dis- 
play  any cdc2-phosphorylated vimentin, showing that cdc2 had 
in fact been  inhibited in  vivo, and that cells were arrested prior 
to metaphase. 
DISCUSSION 
In this paper we describe the enzyme inhibitory properties 
and cellular effects of  roscovitine, a novel, highly efficient and 
selective inhibitor of  some cyclin-dependent kinases. Roscovi- 
tine  belongs  to  a  family  of  C2,  N',  N9-substituted  adenines 
which interact with the ATP-binding site of  cdk [27, 31, 341. 
Kinase specificity of inhibition by roscovitine. Among 25 ki- 
nases tested, only some members of the cdk family are inhibited 
by sub-micromolar concentrations of roscovitine. cdk5 appears 
to be  the  most  sensitive  cdk  to  roscovitine  and  olomoucine 
(Table 1, Fig. 1). On the basis of their sensitivity to C2, N", N9- 
substituted adenines, cdk proteins can be divided in two subfam- 
ilies, cdc2/cdk2/cdk5 (sensitive to roscovitine and olomoucine) 
and cdk4lcdk6 (poorly sensitive to roscovitine and olomoucine). 
This division is also apparent with two other inhibitors, stauro- 
sporine and butyrolactone  I  [29, 301. The relative insensitivity 
of  cdk4 and cdk6 may be related to  the relative evolutionary 
distance of  cdk4lcdk6 from cdc2lcdk21cdk5  [60] : the cdc2 se- 
quence displays 65%, 57%, 44% and 47% identity with cdk2, 
cdk5, cdk4 and cdk6, respectively, while cdk4 and cdk6 share 
71 % identity. Understanding the reasons behind the differential 
sensitivity of  cdc2/cdk2/cdk5  and cdk4lcdk6 to inhibitors will 
certainly be helpful to design cdk4kdk6-specific inhibitors. Sur- 
prisingly,  the effects of roscovitine  on erkl and erk2 are quite 
similar to those of olomoucine (Table 1, Fig. 2). As roscovitine 
is  10-fold more active on cdk than olomoucine, this inhibitor 
presents increased selectivity and should allow  the distinction 
between cdk- and erk-dependent events. Furthermore this infor- 
mation may help in designing erk-selective inhibitors. Two en- 
zymes, myosin light-chain kinase and insulin-receptor tyrosine 
kinase  were  inhibited  by  roscovitine  concentrations  below 
100 pM, in contrast to olomoucine. 
Cellular  effects of  roscovitine:  G2M and  GUS  arrest.  As 
illustrated with starfish and Xenopus oocytes and sea urchin em- 
bryos, roscovitine inhibits the prophaselmetaphase transition  in 
the micromolar range. This effect was also observed with higher 
concentrations of  olomoucine [27, 281. Accumulation of cells in 
late G2 was also observed in tobacco BY-2 cells (Planchais et 
al., unpublished) and with L1210 cells. The most straightforward 
interpretation for these observations is that the in vivo target for 
roscovitine is cdc2lcyclin B. This is further supported by a) the 
in vitro effects of roscovitine on MPF activity in Xenopzts cell- 
free extracts, b) the in  vivo reduced phosphorylation of elonga- 
tion factor 1 in Xenops oocytes treated with roscovitine, c) the 
in  vivo  phosphorylation  (cdc2-specific  sites)  of  vimentin  in 
L1210 cells suppressed by roscovitine. The possibility that ros- 
covitine effects can be accounted for by inhibition of erk protein 
is unlikely  since roscovitine  appears to be  more efficient than 
olomoucine in its cellular effects but not in its effects on erk. 
Accumulation  of  cells  in prophase following release  from an 
aphidicolin block and further treatment with olomoucinehoscov- 
itine has been successfully used to synchronize cells in this late 
part of the cell cycle [61]. Meijer et al. (Eue J. Biochem. 243)  535 
Roscovitine is also able to arrest cells in late G1 as shown 
in  vitro with Xenopus cell-free  extracts, in L1210 cells and in 
tobacco BY-2 cells (Planchais et al., unpublished). We  believe 
that it does so by  inhibiting cdk2lcyclin E and cdk2/cyclin A. 
Cyclin A expression is  a marker  of  for  late G1 phase  in  cell 
proliferation. Cyclin A mRNA induction by  Myc in fibroblasts 
was recently shown to be inhibited by roscovitine, p21 and p27 
Roscovitine acts on many cells at higher concentrations than 
it does on purified enzymes. This could be due to poor perme- 
ability, unfavourable  compartmentalisation,  active  metabolism 
into inactive compounds, presence of  unidentified binding pro- 
teins, high concentrations of  cellular ATP,  or a combination of 
these  factors.  In  addition,  as  cdc2/cyclin  B  activates  its  own 
ubiquitin-dependent  proteolysis  [63,  641,  partial  inhibition  of 
cdc2 may in fact stabilize the residual kinase  activity, thereby 
reducing the cellular effects of a cdk inhibitor. 
[621. 
Cdk inhibitors and apoptosis. Efficient anti-tumour drugs are 
thought to act by  triggering apoptosis in the target tissue [6S- 
681. The relationship between cell cycle and apoptosis is rather 
complex but is starting to be unraveled (reviewed in [68-711). 
Multiple  pathways  lead  to  apoptosis,  some  of  which  require 
active cdc2-cdk2/cyclin A [72] or cdc2/cyclin B [73, 741, while 
others do not apparently require any cdk  [74-77].  Depending 
on the  apoptosis-inducing agonist, T-cell hybridoma A1 1 cells 
enter programmed cell death by a cdk-dependent (anti-CD3) or 
cdk-independent  (dexamethasone) pathway  [74]. Mitotic PC12 
cells undergo cell death when exposed to olomoucine or flavopi- 
ridol,  while  differentiated  PC12  cells  are  protected  from  cell 
death by the same inhibitors [33]. Myc-induced apoptosis is in- 
sensitive to roscovitine, p21 and p27 [62]. 
Apoptosis can be induced either in G1 or in G2. Following 
DNA damage by various chemicals, ultraviolet irradiation or X- 
rays,  some  cells  arrest  in  G1  and  a  p53-dependent  apoptotic 
pathway is induced [78-SO].  In other situations, cells arrest in 
G2/M in response to DNA-damaging agents, X-rays or taxol and 
a p53-independent apoptotic pathway is activated [78, 80-831. 
This pathway may be extremely important in the therapy of tu- 
mours  showing loss of  active p53. Olomoucine  greatly stimu- 
lates  pS3-independent  apoptosis  in  cells  which  have  been  ar- 
rested in G2 by DNA-damaging agents such as mitoxantrone or 
cis-platinum [32]. The apoptosis-inducing effects of roscovitine 
and  olomoucine  are  clearly  p53-independent.  Cdc2  inhibitors 
may thus enhance the therapeutic effects of currently used anti- 
tumour agents, particularly in p53-mutated cells. In this context, 
the cdk inhibitor flavopiridol is entering phase I studies as an 
anti-tumour agent. 
Cdk inhibitors and the nervous system. Roscovitine and olo- 
moucine may contribute to reduce the hyperphosphorylation of 
tau observed during Alzheimer’s disease. The brain of  patients 
afflicted by this disease contains intracellular deposits of abnor- 
mally phosphorylated tau (reviewed [84]). The relationship be- 
tween  abnormal  tau  phosphorylation  and  the  development  of 
Alzheimer’s disease is still unclear. However many of  the tau 
phosphorylation sites have been identified  18.51.  Some of  these 
sites are phosphorylated by cdk5/p35 (reviewed [86]), a brain- 
specific cdk which is particularly sensitive to roscovitine. 
It was recently found that olomoucine and tlavopiridol pre- 
vent  neuronal  cell  death  induced  by  neutrophic  factor  with- 
drawal (nerve growth factor-differentiated PC12 cells and sym- 
pathetic neurons). In contrast, these drugs promote apoptosis of 
mitotic PC12 cells [33]. We  therefore anticipate that cdk inhibi- 
tors may  be useful in the therapy of  some nervous system dis- 
eases. 
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